The Trump administration launched a comprehensive enforcement initiative targeting fraud and waste in federal health benefit programs that serve millions of Americans. The Office of Personnel Management ordered insurance carriers to strengthen fraud prevention controls as part of a coordinated effort with the White House Task Force to Eliminate Fraud. The directive affects health plans covering more than 8.2 million federal employees, family members and other eligible individuals enrolled in government-sponsored programs.
OPM director Scott Kupor confirmed the agency is taking additional steps to safeguard premiums paid by federal employees and taxpayers while protecting beneficiaries. The initiative requires insurance companies to meet the highest standards of accountability. The federal government and enrollees spent approximately $70 billion on the Federal Employees Health Benefits program in fiscal 2024, according to the U.S. Government Accountability Office.
New compliance requirements sent to insurance carriers
OPM partnered with the White House Task Force to Eliminate Fraud to send new compliance expectations to insurance carriers in the Federal Employees Health Benefits and Postal Service Health Benefits programs. The directive instructs carriers to strengthen several key areas of oversight and accountability. Scott Brady, executive director of the White House Task Force, called OPM a valuable partner and leader whose actions will protect taxpayers and the federal workforce.
The compliance requirements focus on multiple fraud prevention areas. Insurance carriers must enhance payment reviews and pharmacy benefit oversight. Companies face stricter subcontractor accountability standards and more rigorous audits. The directive also mandates improved reporting procedures to detect irregularities more quickly. Pharmacy benefit managers, the middlemen who administer prescription drug benefits and negotiate with drugmakers and pharmacies, are specifically targeted in the crackdown.
Data science team to detect fraud and overbilling
OPM is building a specialized data science and audit team in partnership with the agency’s inspector general. The team will review anonymized claims data to detect fraud, waste and overbilling more proactively. This represents a shift from reactive investigations to predictive analytics that can identify suspicious patterns before they result in significant losses. The technical approach aims to catch fraudulent activities earlier in the billing cycle.
The Government Accountability Office issued a report in July 2025 highlighting the need for OPM to do more in managing fraud risks in the Federal Employees Health Benefits program. The report identified multiple risk categories requiring attention:
- Benefit card sharing among unauthorized individuals
- Improper inducements offered to enrollees
- Insufficient or fraudulent documentation submitted for claims
- Kickback schemes involving providers and intermediaries
- Marketing fraud targeting federal employees
- Theft of personally identifiable information
- Provider ineligibility and self-referrals
These identified vulnerabilities formed the basis for the new compliance requirements sent to insurance carriers. The GAO recommendations pushed OPM to implement more aggressive fraud prevention measures across all program operations.
Nationwide Medicaid probe expands enforcement efforts
The announcement marks the latest enforcement action in a broader crackdown on medical program fraud. The Centers for Medicare and Medicaid Services directed all 50 states to submit plans to revalidate high-risk Medicaid providers in April. The directive targets providers subject to less rigorous enrollment standards or those operating without a National Provider Identifier.
Vice President JD Vance, who leads the task force, amplified the enforcement call in May during a news conference. He warned that states could lose federal funding if they fail to aggressively pursue Medicaid fraud. The threat of funding cuts represents a significant escalation in federal enforcement tactics. State governments now face financial consequences for inadequate fraud prevention measures.
Minnesota case highlights scale of medical fraud
The push comes amid heightened focus on large-scale fraud cases that have exposed systemic vulnerabilities. Minnesota’s $250 million “Feeding Our Future” scheme became a national flashpoint in recent months, drawing attention to the scope of fraud possible in government programs. The case involved funds intended for child nutrition programs that were allegedly diverted through fraudulent claims. Federal prosecutors charged dozens of defendants in connection with the scheme.
The Minnesota case illustrated how fraudsters exploited weak oversight systems to steal taxpayer money over extended periods. The scheme operated for years before authorities detected the fraud. Investigators found that inadequate verification procedures allowed false claims to pass through multiple approval stages. The case prompted calls for stronger preventive measures across all federal benefit programs.
House Republicans launch parallel investigation
Congressional Republicans have joined the enforcement push with their own investigative efforts. House GOP leaders launched a new task force to examine alleged Medicaid fraud totaling $250 billion in Ohio. The investigation runs parallel to the administration’s enforcement actions and signals bipartisan concern about program integrity. Congressional oversight committees are requesting documents and testimony from state officials responsible for program administration.
The multi-pronged approach combines administrative directives, data analytics, congressional oversight and potential funding penalties. Federal authorities are deploying resources across multiple agencies to identify and prosecute fraud cases. The coordinated effort reflects growing political pressure to demonstrate fiscal responsibility in government health programs. Insurance carriers and pharmacy benefit managers face increased scrutiny of their billing practices and payment approvals.
The administration’s focus on pharmacy benefit managers addresses long-standing concerns about transparency in drug pricing. These middlemen negotiate rebates with pharmaceutical companies and determine which medications are covered by insurance plans. Critics argue the complex arrangements lack adequate oversight and create opportunities for hidden fees and kickbacks. The new compliance requirements aim to bring more accountability to these transactions and ensure federal employees receive the drug benefits they are entitled to without excessive costs.
